SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT
Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.
1 - 26 . (canceled)
27 . Omecamtiv mecarbil dihydrochloride crystalline form C characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.7±0.2, 14.8±0.2, 17.4±0.2, 20.6±0.2, and 26.2±0.2° 2 θ using Cu Kα radiation.
28 . The crystalline form of claim 27 , wherein the XRPD pattern further comprises peaks at 8.7±0.2, 22.0±0.2, 27.1±0.2, and 27.7±0.2° 2 θ using Cu Kα radiation.
29 . A method of preparing omecamtiv mecarbil dihydrochloride hydrate comprising exposing the crystalline form of claim 27 to 15% relative humidity or higher to form omecamtiv mecarbil dihydrochloride hydrate.
30 . The method of claim 29 , wherein the omecamtiv mecarbil dihydrochloride hydrate has an x-ray powder diffraction pattern (XRPD) comprising peaks at 6.6±0.2, 14.9±0.2, 20.1±0.2, 21.4±0.2, and 26.8±0.2° 2 θ using Cu Kα radiation.
31 . The method of claim 30 , wherein the XRPD pattern further comprises peaks at 8.4±0.2, 24.2±0.2, 26.0±0.2, and 33.3±0.2° 2 θ using Cu Kα radiation.
32 . The method of claim 29 , wherein the omecamtiv mecarbil dihydrochloride hydrate has an x-ray powder diffraction pattern (XRPD) comprising peaks at 6.6±0.2, 8.4±0.2, 14.9±0.2, 15.4±0.2, and 26.8±0.2° 2 θ using Cu Kα radiation.
33 . The method of claim 32 , wherein the XRPD pattern further comprises peaks at 16.3±0.2, 19.5±0.2, 21.8±0.2, 22.8±0.2, 27.7±0.2, and 28.4±0.2° 2 θ using Cu Kα radiation.
34 . The method of claim 29 , wherein the omecamtiv mecarbil dihydrochloride hydrate has an x-ray powder diffraction pattern (XRPD) comprising peaks at 6.6±0.2, 14.9±0.2, 16.3±0.2, 19.5±0.2, and 26.8±0.2° 2 θ using Cu Kα radiation.
35 . The method of claim 34 , wherein the XRPD pattern further comprises peaks at 21.8±0.2, 22.8±0.2, 27.7±0.2, and 28.4±0.2° 2 θ using Cu Kα radiation.